Goa Fda

• 

  Lupin Receives Inspection Report From USFDA For Goa Manufacturing Facility

  The USFDA has determined that the inspection classification of the facility is VAI, the company said in a statement.

• 

  Lupin Falls After US FDA Inspects Goa Facility With Seven Observations

  Lupin shares have so far this year fallen 2.73 per cent, sharply underperforming the benchmark Sensex which has advanced 23.6 per cent.

• 

  Goa To Start Using Drug Shunned By US Regulator For Covid Treatment

  Goa has given the nod for the use of an anti-parasitic drug as preventive treatment for all adults against COVID-19. The drug, Ivermectin, has been disapproved of by the US Food and Drug Administration (FDA).

• 

  Cipla Shares Fall 6% After US Regulator's Warning Letter On Goa Facility

  Cipla Share Price: Cipla said it will work closely with the US Food and Drug Administration (FDA) to comprehensively address all the observations.

• 

  Goa Minister Apologises For Formalin Remark, Basa Fish On FDA Radar

  Even though Goa Chief Minister Manohar Parrikar has refused to answer whether fish sold in Goa actually contained formalin, Health Minister Vishwajit Rane on Friday apologised publicly for his use of term "permissible limit" which has now become a butt joke in social media.

• 

  Will Ban Fish Import If Impurities Are Found: Goa Minister

  Goa will not mind banning the import of fish if impurities are found in it, state Food and Drugs Administration Vishwajit Rane said today.

• 

  Lupin Looks To Clean Up Its Act As FDA Steps Up Inspections

  Often dubbed "the pharmacy of the world", India is home to the most FDA-approved plants outside of the United States

• 

  Lupin Expects US FDA Approvals From Goa Factory In Two Months

  Lupin has about a dozen new products ready for export to the U.S. from the Goa facility, each worth about $20 million to $30 million in revenue, that have been delayed, Managing Director Nilesh Gupta said.

• 

  Lupin Gives Up Gains On FDA Observations For Gujarat Plant

  Shares of Lupin surged for the second day, following the US regulator's partial clearance for the drugmaker's Goa plant. Lupin shares jumped as much as 3.4 per cent to hit a high of Rs 1,712.30 today, after rising 6 per cent yesterday.

• 

  Permissible Potassium Bromate Found In 4 Bread Samples: Goa's Food and Drugs Administration

  Goa's Food and Drugs Administration (FDA) today said four of the 18 bread samples collected in the state tested positive for potassium bromate, but within permissible limits.

• 

  Investors Overlook Lupin's Q4 Beat, Shares Tumble Over 9%

  Lupin shares sank over 8 per cent on Friday, even though analysts described the drugmaker's Q4 results as positive.

• 

  Indoco Remedies Surges On FDA Boost For Goa Facility

  The plant has a capacity to manufacture 2.2 billion tablets, 32 million bottles of liquid orals, 16 million tubes of creams and ointments and 60 million capsules of hard gelatin.

• 

  Lupin Leads Selloff in Pharma Shares, Hits 52-Week Low

  Lupin shares have been reeling under selling pressure following adverse observations about the company's Goa plant by the US Food and Drug Administration earlier this week.

• 

  Lupin Receives 9 Observations From US Regulator for Goa Plant

  Drug major Lupin on Tuesday said it has received nine observations relating to inadequacy and adherence to operating norms for its manufacturing plant in Goa from the US Food and Drug Administration (FDA).

• 

  Maggi Noodles Deemed Safe for First Time Since Ban Was Ordered

  For the first time since the hugely popular snack was banned across India, Maggi Noodles has passed a test which establishes it complies with food safety standards.